Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2024-07-31 DOI:10.3390/curroncol31080327

Winson Y. Cheung, Chantelle Carbonell, Vishal Navani, Randeep S. Sangha, Emmanuel M. Ewara, Julia Elia-Pacitti, Sandra Iczkovitz, Tamer N. Jarada, Matthew T. Warkentin

{"title":"Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta","authors":"Winson Y. Cheung, Chantelle Carbonell, Vishal Navani, Randeep S. Sangha, Emmanuel M. Ewara, Julia Elia-Pacitti, Sandra Iczkovitz, Tamer N. Jarada, Matthew T. Warkentin","doi":"10.3390/curroncol31080327","DOIUrl":null,"url":null,"abstract":"There is limited information on the treatment trajectory and outcomes of patients with advanced cEGFRm NSCLC treated with osimertinib in routine clinical practice in Canada. By using and analyzing population-based administrative data and detailed chart abstraction in the province of Alberta, our objective was to capture Canadian-specific real-world treatment patterns, health outcomes, and healthcare resource utilization (HCRU) in advanced cEGFRm NSCLC patients who were (a) treated with osimertinib and (b) those receiving treatment after osimertinib. In our study cohort, we found that the overall survival rates for real-world patients receiving osimertinib were less favorable than those observed in clinical trials (24.0 versus 38.6 months). The attrition rate after osimertinib was substantial and high HCRU persisted across many years after diagnosis and treatment. This study provides important real-world evidence on contemporary survival, treatment patterns, and healthcare use among cEGFRm NSCLC patients treated with osimertinib and suggests that further research efforts are needed to improve therapeutic options in both the first and subsequent line settings.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31080327","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

There is limited information on the treatment trajectory and outcomes of patients with advanced cEGFRm NSCLC treated with osimertinib in routine clinical practice in Canada. By using and analyzing population-based administrative data and detailed chart abstraction in the province of Alberta, our objective was to capture Canadian-specific real-world treatment patterns, health outcomes, and healthcare resource utilization (HCRU) in advanced cEGFRm NSCLC patients who were (a) treated with osimertinib and (b) those receiving treatment after osimertinib. In our study cohort, we found that the overall survival rates for real-world patients receiving osimertinib were less favorable than those observed in clinical trials (24.0 versus 38.6 months). The attrition rate after osimertinib was substantial and high HCRU persisted across many years after diagnosis and treatment. This study provides important real-world evidence on contemporary survival, treatment patterns, and healthcare use among cEGFRm NSCLC patients treated with osimertinib and suggests that further research efforts are needed to improve therapeutic options in both the first and subsequent line settings.

查看原文本刊更多论文

阿尔伯塔省接受奥希替尼治疗的晚期普通表皮生长因子受体阳性非小细胞肺癌患者的实际治疗模式、健康结果和医疗资源使用情况

关于加拿大常规临床实践中使用奥希替尼治疗晚期cEGFRm NSCLC患者的治疗轨迹和疗效的信息非常有限。通过使用和分析阿尔伯塔省基于人口的行政数据和详细的病历摘要，我们的目标是捕捉加拿大特异性的真实世界治疗模式、健康结果和医疗资源利用率（HCRU），这些晚期 cEGFRm NSCLC 患者（a）接受了奥希替尼治疗，（b）在接受奥希替尼治疗后又接受了奥希替尼治疗。在我们的研究队列中，我们发现现实世界中接受奥希替尼治疗的患者的总生存率低于临床试验中观察到的数据（24.0 个月对 38.6 个月）。奥希替尼治疗后的自然减员率很高，高HCRU在诊断和治疗后的许多年中持续存在。这项研究为接受奥希替尼治疗的 cEGFRm NSCLC 患者提供了有关当代生存、治疗模式和医疗保健使用情况的重要真实证据，并表明需要进一步开展研究，以改进一线和后续治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.